Beta Bionics’ IPO marks one of the largest public offerings for an Orange County-based company in over three years, second ...

Beta Bionics (BBNX) leads innovation in the diabetes treatment market with its groundbreaking iLet Bionic Pancreas technology ...

Stock analysts at StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO – Get Free Report) in a report released on Saturday. The firm set a “hold” rating on the stock. Several other ...

Beta Bionics has begun life as a public company with a $204m initial public offering (IPO), significantly higher than its anticipated target. The US-based company sold 12 million shares of its common ...

The company estimates that its install base surpassed 15,000 by the end of last year, leading to sales of more than $20 million in the fourth quarter.

Thursday marked the Nasdaq Global Market debut of Beta Bionics, Inc. as its initial public offering (IPO) opened for trading at $22 per share. The medical device company, recognized for its ...

Insulin delivery device maker Beta Bionics said on Wednesday it was targeting a valuation of as much as $615.9 million in its initial public offering in the United States, underscoring a gradual ...

In a groundbreaking development for hearing healthcare in India, Dr. Rao's ENT Hospital, in collaboration with Advanced Bionics, announces the launch of the first-ever Asia Pacific Advanced ...

Beta Bionics closed an upsized IPO, raising approximately $212.1 million, trading on Nasdaq under the ticker BBNX. Beta Bionics, Inc. has successfully completed an upsized initial public offering ...

Beta Bionics announces upsized IPO of 12 million shares at $17 each, aiming for $204 million in gross proceeds. Beta Bionics, Inc., a leader in diabetes management solutions, has announced the ...